3B BlackBio Dx Ltd Full Year Financials

Revenue from operations for FY 2025-26: ₹141.92 crore
Profit After Tax for FY 2025-26: ₹59.93 crore

Reader Takeaway: Acquisition integration fuels strong growth, but geopolitical risks and competition present challenges.

What just happened

3B BlackBio Dx Ltd announced its consolidated financial results for the full fiscal year 2025-26. The company reported a significant jump in revenue from operations, reaching ₹141.92 crore, a 47% increase compared to ₹96.47 crore in the prior fiscal year. Profit After Tax (PAT) also saw robust growth, rising by 26% to ₹59.93 crore from ₹47.69 crore in FY 2024-25.

Why this matters

This performance indicates strong top-line expansion and improved profitability, driven partly by the successful integration of its subsidiary, Coris BioConcept SRL. The growth highlights the company's strategic moves in the diagnostics and specialty chemicals sectors. Investors will be watching how the company manages the headwinds mentioned in the report.

The backstory

The company's revenue for FY26 was boosted by ₹35.91 crore from its Coris BioConcept division. The MDx business contributed ₹21.41 crore from non-Covid export sales. However, the agrochemicals division's export sales declined to ₹2.78 crore due to geopolitical issues in markets like Bangladesh.

The prior fiscal year, FY25, saw revenue at ₹96.47 crore and PAT at ₹47.69 crore. The current year's profit includes a one-time benefit from the HAT Order.

What changes now

3B BlackBio Dx Ltd is actively pursuing US FDA registration for its AMR product line and is transitioning its MDx portfolio to comply with EU IVDR regulations. The company is also evaluating further mergers and acquisitions in the IVD sector in the EU and USA. The agrochemicals division will focus on government contracts and existing clients.

Risks to watch

Geopolitical tensions in export markets like Bangladesh and the Middle East are impacting both the Agrochemical and MDx segments. The company faces stiff competition in the diagnostics sector, especially from Chinese players in infectious diseases, potentially pressuring margins. Additionally, a liberal credit policy to maintain market share has led to higher debtor levels.

Peer comparison

(No peer comparison data provided in the filing)

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹141.92 crore (up 47% YoY)
• Consolidated PAT FY26: ₹59.93 crore (up 26% YoY)
• Coris BioConcept contribution: ₹35.91 crore (FY26)
• MDx non-Covid export sales: ₹21.41 crore (FY26)
• Agrochemicals export sales: ₹2.78 crore (FY26) (down due to geopolitical issues)

What to track next

Investors should monitor the progress of US FDA approvals, compliance with EU IVDR regulations, the success of future M&A activities, and the company's ability to navigate geopolitical challenges and competitive pressures in its key markets.